QPS Neuropharmacology | 美體產業公開資訊

QPSNeuropharmacologyisapreclinicalfull-servicecontractresearchorganization(CRO)focusingonCNSdiseases,Orphandiseases,mentaldisorders.

Scantox offers a comprehensive portfolio of drug discovery, development and CMC/Analytical services to support pharmaceutical, biotech and medical device industries.

We are specialists in Neuropharmacology and offer preclinical studies in CNS diseases, Rare Diseases and Mental Disorders but also within Oncology, Infectious diseases along with PK/PD studies in a variety of species. The on-site availability of highly predictive disease models and unparalleled experience with studies performed for biopharmaceutical companies of all sizes makes Scantox the first choice for most CNS drug development needs. Validated transgenic and non-transgenic in vitro and in vivo models cover most targets of Alzheimer’s Disease (AD), Parkinson’s Disease (PD), Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Dementia (FTD), Niemann-Pick Disease (NPC1), Gaucher Disease, Autism Spectrum Disorder (ASD), Schizophre...